PD-1 Làm Giảm Chức Năng Của Các Tế Bào Dendritic Xâm Nhập Khối U Buồng Trứng Bằng Cách Vô Hiệu Hóa NF-κB

Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, 348, 203, 10.1056/NEJMoa020177

Shiao, 2011, Immune microenvironments in solid tumors: new targets for therapy, Genes Dev, 25, 2559, 10.1101/gad.169029.111

Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, 10, 942, 10.1038/nm1093

Preston, 2013, The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer, PLoS ONE, 8, e80063, 10.1371/journal.pone.0080063

Knutson, 2015, Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer, Cancer Immunol Immunother, 64, 1495, 10.1007/s00262-015-1753-x

Canioni, 2008, High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial, J Clin Oncol, 26, 440, 10.1200/JCO.2007.12.8298

Engelhardt, 2012, Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells, Cancer Cell, 21, 402, 10.1016/j.ccr.2012.01.008

Gorgun, 2013, Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans, Blood, 121, 2975, 10.1182/blood-2012-08-448548

Scarlett, 2012, Ovarian cancer progression is controlled by phenotypic changes in dendritic cells, J Exp Med, 209, 495, 10.1084/jem.20111413

Krempski, 2011, Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer, J Immunol, 186, 6905, 10.4049/jimmunol.1100274

Harimoto, 2013, Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells, Immunol Cell Biol, 91, 545, 10.1038/icb.2013.38

Perrot, 2007, Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage, J Immunol, 178, 2763, 10.4049/jimmunol.178.5.2763

Iwamoto, 2003, Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas, Int J Cancer, 104, 92, 10.1002/ijc.10915

Sandel, 2005, Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization, Clin Cancer Res, 11, 2576, 10.1158/1078-0432.CCR-04-1448

Whiteside, 2006, Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention, Semin Cancer Biol, 16, 3, 10.1016/j.semcancer.2005.07.008

Michielsen, 2011, Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer, PLoS ONE, 6, e27944, 10.1371/journal.pone.0027944

Chiba, 2012, Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1, Nat Immunol, 13, 832, 10.1038/ni.2376

Min, 2013, Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways, J Immunol, 190, 2437, 10.4049/jimmunol.1202282

Hargadon, 2013, Tumor-altered dendritic cell function: implications for anti-tumor immunity, Front Immunol, 4, 192, 10.3389/fimmu.2013.00192

Liu, 2009, Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I, J Immunol, 182, 6207, 10.4049/jimmunol.0803926

Wherry, 2011, T cell exhaustion, Nat Immunol, 12, 492, 10.1038/ni.2035

Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331

Sheppard, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett, 574, 37, 10.1016/j.febslet.2004.07.083

Okazaki, 2001, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine, Proc Natl Acad Sci U S A, 98, 13866, 10.1073/pnas.231486598

Knutson, 2006, IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice, J Immunol, 177, 84, 10.4049/jimmunol.177.1.84

Roby, 2000, Development of a syngeneic mouse model for events related to ovarian cancer, Carcinogenesis, 21, 585, 10.1093/carcin/21.4.585

Behrens, 2008, The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity, Blood, 111, 1472, 10.1182/blood-2007-10-117184

Knutson, 2004, Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice, Cancer Res, 64, 1146, 10.1158/0008-5472.CAN-03-0173

Hirano, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res, 65, 1089, 10.1158/0008-5472.1089.65.3

Tzeng, 2012, PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model, PLoS ONE, 7, e39179, 10.1371/journal.pone.0039179

Goldberg, 2007, Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells, Blood, 110, 186, 10.1182/blood-2006-12-062422

Tsushima, 2007, Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy, Blood, 110, 180, 10.1182/blood-2006-11-060087

Ma, 2012, Tumor associated regulatory dendritic cells, Semin Cancer Biol, 22, 298, 10.1016/j.semcancer.2012.02.010

Ma, 2013, Dendritic cells in the cancer microenvironment, J Cancer, 4, 36, 10.7150/jca.5046

Karyampudi, 2014, Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody, Cancer Res, 74, 2974, 10.1158/0008-5472.CAN-13-2564

Riley, 2009, PD-1 signaling in primary T cells, Immunol Rev, 229, 114, 10.1111/j.1600-065X.2009.00767.x

Zhang, 2008, Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses, PLoS One, 3, e3097, 10.1371/journal.pone.0003097

Sun, 2011, Non-canonical NF-kappaB signaling pathway, Cell Res, 21, 71, 10.1038/cr.2010.177

Yoshimura, 2001, Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI, Eur J Immunol, 31, 1883, 10.1002/1521-4141(200106)31:6<1883::AID-IMMU1883>3.0.CO;2-V

Yoshimura, 2001, Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines, Int Immunol, 13, 675, 10.1093/intimm/13.5.675

Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J Immunol, 173, 945, 10.4049/jimmunol.173.2.945

Agata, 1996, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, Int Immunol, 8, 765, 10.1093/intimm/8.5.765

Oestreich, 2008, NFATc1 regulates PD-1 expression upon T cell activation, J Immunol, 181, 4832, 10.4049/jimmunol.181.7.4832

Austin, 2014, STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells, J Immunol, 192, 4876, 10.4049/jimmunol.1302750

Pisa, 1992, Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies, Proc Natl Acad Sci U S A, 89, 7708, 10.1073/pnas.89.16.7708

Kaebisch, 2014, Helicobacter pylori cytotoxin-associated gene A impairs human dendritic cell maturation and function through IL-10-mediated activation of STAT3, J Immunol, 192, 316, 10.4049/jimmunol.1302476

Kamphorst, 2013, Manipulating the PD-1 pathway to improve immunity, Curr Opin Immunol, 25, 381, 10.1016/j.coi.2013.03.003

Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25, 9543, 10.1128/MCB.25.21.9543-9553.2005

Patsoukis, 2012, Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation, Sci Signal, 5, ra46, 10.1126/scisignal.2002796

Watts, 2010, TLR signalling regulated antigen presentation in dendritic cells, Curr Opin Immunol, 22, 124, 10.1016/j.coi.2009.12.005

You, 2001, Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor, J Exp Med, 193, 101, 10.1084/jem.193.1.101

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Weber, 2013, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma, J Clin Oncol, 31, 4311, 10.1200/JCO.2013.51.4802

Topalian, 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol, 32, 1020, 10.1200/JCO.2013.53.0105